Skip to main content
Clinical Trials/ITMCTR2022000037
ITMCTR2022000037
Not yet recruiting
Phase 1

A study on strategies for the prevention and treatment of metabolic syndrome in Chinese medicine and the preliminary construction of a predictive model for cardiovascular disease risk - a prospective cohort study

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\) age 30\-80 years, gender not limited;
  • (2\) meet the diagnostic criteria for metabolic syndrome and any of the above TCM evidence types;
  • (3\) have good compliance;
  • (4\) sign the informed consent form.

Exclusion Criteria

  • (1\) Exclusion of other primary diseases causing (chronic kidney disease, chronic liver disease, hypothyroidism) abnormalities in blood glucose, lipids and blood pressure.
  • (2\) Combination of severe cardiovascular and cerebrovascular diseases, such as heart failure, severe hypertension, cerebral haemorrhage, etc.
  • (3\) Combined with severe liver function abnormalities (ALT or AST reaching more than 3 times the upper limit of normal), endocrine diseases, malignant tumours and autoimmune diseases
  • (4\) Women who are pregnant, preparing for pregnancy or breastfeeding.
  • (5\) Allergy and hypersensitivity to the components of the drug used in this study.
  • (6\) Those who are participating in other clinical trials or have participated in clinical trials of other drugs for less than 1 month.

Outcomes

Primary Outcomes

Not specified

Similar Trials